SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Down 35.3% in January

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a large decrease in short interest in January. As of January 15th, there was short interest totalling 36,500 shares, a decrease of 35.3% from the December 31st total of 56,400 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 98,100 shares, the short-interest ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Craig Hallum assumed coverage on shares of SAB Biotherapeutics in a report on Wednesday, October 9th. They set a “buy” rating and a $11.00 price objective on the stock. Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a report on Thursday, November 7th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $12.40.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ:SABS opened at $2.07 on Wednesday. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a 52-week low of $2.01 and a 52-week high of $6.30. The company has a 50 day moving average of $3.63 and a two-hundred day moving average of $3.13.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. Sell-side analysts predict that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

An institutional investor recently bought a new position in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC purchased a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned approximately 0.21% of SAB Biotherapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.